Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Rhea-AI Summary

Cadrenal Therapeutics, Inc. (CVKD) announced that its Chief Medical Officer will participate in a fireside chat at the Lytham Partners 2024 Investor Select Conference. The company will also host one-on-one meetings with investors. The webcasted fireside chat is scheduled for February 1, 2024, and can be accessed online. Management will be participating in virtual one-on-one meetings throughout the event. Further information on the conference is available at the provided link.

PONTE VEDRA, Fla., Jan. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain conditions, announced today that Douglas Losordo, M.D., Chief Medical Officer of Cadrenal, will participate in a fireside chat moderated by Joe Pantginis, Ph.D., Managing Director of Research at H.C. Wainwright & Co., at the Lytham Partners 2024 Investor Select Conference. Management will also host one-on-one meetings with investors.

Company Webcast
The webcasted fireside chat will take place at 11:00 am ET on Thursday, February 1, 2024. The webcast can be accessed at https://wsw.com/webcast/lytham10/cvkd/2081408 or on the Company's website at https://www.cadrenal.com/investors/. The webcast will also be available for replay following the event.

1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/select2024invreg/.

Further information on the conference is available at https://lythampartners.com/select2024.

ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain conditions. Tecarfarin has orphan drug and fast track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end stage kidney disease (ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.  

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com 

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-a-fireside-chat-at-the-lytham-partners-2024-investor-select-conference-on-february-1-2024-302042716.html

SOURCE Cadrenal Therapeutics, Inc.

FAQ

When is the webcasted fireside chat scheduled?

The webcasted fireside chat is scheduled for February 1, 2024 at 11:00 am ET.

How can the webcast be accessed?

The webcast can be accessed at https://wsw.com/webcast/lytham10/cvkd/2081408 or on the Company's website at https://www.cadrenal.com/investors/.

How can investors arrange one-on-one meetings with management?

To arrange a meeting with management, investors can contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/select2024invreg/.

Where can further information on the conference be found?

Further information on the conference is available at https://lythampartners.com/select2024.